search
Back to results

Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed (REDUCE-PMR-1)

Primary Purpose

Polymyalgia Rheumatica

Status
Recruiting
Phase
Phase 3
Locations
Netherlands
Study Type
Interventional
Intervention
Rituximab
Placebo
Sponsored by
Sint Maartenskliniek
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Polymyalgia Rheumatica

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Polymyalgia rheumatica diagnosis fullfilling the 2012 EULAR/ACR classification criteria
  • Diagnoses less than 12 weeks ago
  • Glucocorticoid treatment less than 8 weeks and with dose equivalent of prednisolone ≤ 25mg/day
  • Informed consent

Exclusion Criteria:

  • treatment with systemic immunosuppressants (other than glucocorticoids) 3 months prior to inclusion;
  • (clinical) suspect concomitant giant cell arteritis or other rheumatic inflammatory diseases;
  • concomitant conditions that might significantly interfere with PMR pain or movement evaluation as judged by the investigator;
  • previous hypersensitivity for RTX or contra-indications to RTX.

Sites / Locations

  • Sint MaartensklineikRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Rituximab

Placebo

Arm Description

1000mg rituximab intravenously once

0mg rituximab (placebo) intravenously once

Outcomes

Primary Outcome Measures

Between group difference in percentage of patients in glucocorticoid-free remission
Between group difference in percentage of patients in glucocorticoid-free remission (PMR activity score < 10) at week 52

Secondary Outcome Measures

Percentage of patients in glucocorticoid-free remission
Percentage of patients in glucocorticoid-free remission
Percentage of patients with glucocorticoid dose of ≤5mg/day
Percentage of patients with glucocorticoid dose of ≤5mg/day
Number of relapses
Number of relapses
Time to glucocorticoid-free remission
Time to glucocorticoid-free remission in days during the study period
Time to relapse
Time to relapse in days during the study period
Cumulative glucocorticoid dose
Cumulative glucocorticoid dose
Percentage of patients needing RTX/Placebo retreatment
Percentage of patients needing RTX/Placebo retreatment
Adverse events
Adverse events

Full Information

First Posted
September 6, 2022
Last Updated
May 22, 2023
Sponsor
Sint Maartenskliniek
Collaborators
Dutch Arthritis Association, ZonMw: The Netherlands Organisation for Health Research and Development
search

1. Study Identification

Unique Protocol Identification Number
NCT05533125
Brief Title
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed
Acronym
REDUCE-PMR-1
Official Title
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 1, 2023 (Actual)
Primary Completion Date
January 2026 (Anticipated)
Study Completion Date
January 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sint Maartenskliniek
Collaborators
Dutch Arthritis Association, ZonMw: The Netherlands Organisation for Health Research and Development

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Polymyalgia rheumatica (PMR) is prevalent among elderly. Untreated, it leads to major reduction in quality of life. Glucocorticoids are the cornerstone of treatment, but have drawbacks, warranting glucocorticoid sparing treatment. A proof of concept study on Rituximab (RTX) vs placebo showed efficacy in 48 vs 21%(p=0.049) in glucocorticoid free remission after 21 weeks (Marsman et al. 2021). Though promising, the short study duration and small sample size require further confirmation. Therefore a larger randomised controlled trial with longer follow up will be performed on RTX efficacy on glucocorticoid free remission in newly diagnosed PMR patients during glucocorticoid taper.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Polymyalgia Rheumatica

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
114 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Rituximab
Arm Type
Experimental
Arm Description
1000mg rituximab intravenously once
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
0mg rituximab (placebo) intravenously once
Intervention Type
Drug
Intervention Name(s)
Rituximab
Other Intervention Name(s)
Rixathon, MabThera, Ruxience, Truxima
Intervention Description
Rituximab 1000mg in 250ml NaCl 0.9% intravenously with usual premedication
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo in 250ml NaCl 0.9% intravenously with usual premedication
Primary Outcome Measure Information:
Title
Between group difference in percentage of patients in glucocorticoid-free remission
Description
Between group difference in percentage of patients in glucocorticoid-free remission (PMR activity score < 10) at week 52
Time Frame
At week 52
Secondary Outcome Measure Information:
Title
Percentage of patients in glucocorticoid-free remission
Description
Percentage of patients in glucocorticoid-free remission
Time Frame
21 weeks
Title
Percentage of patients with glucocorticoid dose of ≤5mg/day
Description
Percentage of patients with glucocorticoid dose of ≤5mg/day
Time Frame
52 weeks
Title
Number of relapses
Description
Number of relapses
Time Frame
52 weeks
Title
Time to glucocorticoid-free remission
Description
Time to glucocorticoid-free remission in days during the study period
Time Frame
52 weeks
Title
Time to relapse
Description
Time to relapse in days during the study period
Time Frame
52 weeks
Title
Cumulative glucocorticoid dose
Description
Cumulative glucocorticoid dose
Time Frame
52 weeks
Title
Percentage of patients needing RTX/Placebo retreatment
Description
Percentage of patients needing RTX/Placebo retreatment
Time Frame
52 weeks
Title
Adverse events
Description
Adverse events
Time Frame
52 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Polymyalgia rheumatica diagnosis fulfilling the 2012 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria Diagnoses less than 12 weeks ago Glucocorticoid treatment less than 8 weeks and with dose equivalent of prednisolone ≤ 30 mg/day Informed consent Exclusion Criteria: treatment with systemic immunosuppressants (other than glucocorticoids) 3 months prior to inclusion; (clinical) suspect concomitant giant cell arteritis or other rheumatic inflammatory diseases; concomitant conditions that might significantly interfere with PMR pain or movement evaluation as judged by the investigator; previous hypersensitivity for RTX or contra-indications to RTX.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pauline Bovens, MSc
Phone
0031243272575
Email
p.bovens@maartenskliniek.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Noortje Kooijman, MSc
Phone
0031243272948
Email
n.kooijman@maartenskliniek.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Aatke van der Maas, MD PhD
Organizational Affiliation
Sint Maartenskliniek
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sint Maartensklineik
City
Ubbergen
State/Province
Gelderland
ZIP/Postal Code
6574 NA
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pauline Bovens
Phone
0031243272575
Email
p.bovens@maartenskliniek.nl
First Name & Middle Initial & Last Name & Degree
Noortje Kooijman
Phone
0031243272948
Email
n.kooijman@maartenskliniek.nl
First Name & Middle Initial & Last Name & Degree
Aatke van der Maas

12. IPD Sharing Statement

Learn more about this trial

Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed

We'll reach out to this number within 24 hrs